Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...

Forty years after the release of Atwood’s seminal novel, we are witnessing the echoes of real-life horror stories that inspired her to tell the tale.

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...

BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

Hulu is nearing a series order for 'The Handmaid’s Tale' spinoff 'The Testaments' before the hit show's final season ...

The Handmaid’s Tale creator Bruce Miller has reportedly been working on the show for “several years” now, and stepped down as ...

One of Hulu’s first original series is coming the beginning of the end on Hulu. When does ’The Handmaid’s Tale’ return?